Your Search Returned 143 tagged news reports
WellnessFX, a San Francisco-based start-up that helps consumers get comprehensive blood tests that go far beyond typical drug panels, recently secured $4 million of Series B venture funding and is preparing to launch its various biomarker-based drug
Font Resize The Chieftain They've always been close, but now they share more than love. When Shay Segura says she owes her life to her son, Bryan Cesario, she's not joking. Three months ago, Cesario donated part of his liver to Segura, who was near
The company has selected Chennai Medipoint as distributor in India, Nepal, Bangladesh, Sri Lanka and the Maldives. Innovative Biotech, a subsidiary of Rotary Engineering, was named as the distributor in Singapore, Malaysia and Myanmar. Critical
Posted by Derek I've been saved the trouble of demolishing this J...I really hate to say such things, but this appears to be one of the worst papers that journal has published in quite a while. The authors start out with a small, poorly documented
Text Size The Washington Post Pirates used to say that dead men tell no tales. Of course, the buccaneers had never heard of the polymerase chain reaction. Dead men turn out to be loaded with information if you can get your hands on them or better yet,
F grant BioMarCare and US co Ariadne Diagnostics will develop biomarkers for predicting colon cancer patients' response to drugs. F) for a joint project with US company Ariadne Diagnostics LLC, to develop a panel of biomarkers to predict the response
Newswise One in eight women will be diagnosed with breast cancer during her lifetime. The earlier cancer is detected, the better the chance of successful treatment and long-term survival. However, early cancer diagnosis is still challenging as
Emami launches Zandu Gluco Charge Kolkata, Apr 2 : Emami Limited, a Rs 3500 crore diversified business conglomerate, has launched Zandu Gluco Charge a glucose based energy drink mix with Vitamin C- in the West Bengal market. N. Krishnamohan, CEO
The partnership is aimed at identifying biomarkers that may lead to the development of a molecular companion diagnostic test to help identify patients likely to respond to a Sanofi investigational agent.
Over the last few decades there has been an explosion in the discovery of biomarkers for diagnosis, disease monitoring, and prognostic evaluation.